|Videos|February 23, 2022
- Vol 50 No 06
- Volume 50
- Issue 06
Urology Times 50 Innovations Series: Clean intermittent catheterization
Author(s)Urology Times staff
"Intermittent catheterization is an important concept in urology, and it has a long history," says John Stoffel, MD.
Advertisement
In this installment of Urology Times®' 50th Anniversary Innovation Celebration series, John Stoffel, MD, discusses the development of clean intermittent catheterization and how it has improved the care of patients with urologic conditions. Stoffel is a Professor of Urology, and Chief of the Division Neurourology & Pelvic Reconstruction in the Department of Urology at the University of Michigan in Ann Arbor.
Articles in this issue
over 4 years ago
The role of mediation in medical malpractice litigationover 4 years ago
How do you bill for a 75-minute audio-only E/M visit?over 4 years ago
Telemedicine’s uncertain future in urologyover 4 years ago
Part D data reveal how urologists are prescribing antibioticsover 4 years ago
Same-side shock wave lithotripsy, URS present coding questionsover 4 years ago
What to consider when weighing pre-tax, Roth IRAsalmost 5 years ago
Dr. Amarasekera on supporting sexual minorities in healthcareAdvertisement
Related to this article
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5